Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

FED 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Lymphoma 46Lymphoma, Non-Hodgkin 33Lymphoma, Large B-Cell, Diffuse 32Lymphoma, Mantle-Cell 25Lymphoma, Follicular 21Hodgkin Disease 21Lymphoma, Large-Cell, Immunoblastic 16Glioblastoma 16Leukemia, Lymphocytic, Chronic, B-Cell 15Burkitt Lymphoma 15Brain Neoplasms 14Multiple Myeloma 13Gliosarcoma 13Precursor Cell Lymphoblastic Leukemia-Lymphoma 12Central Nervous System Neoplasms 12Leukemia 10Neoplasms, Plasma Cell 9Lymphoma, B-Cell, Marginal Zone 9Glioma 9Astrocytoma 9Oligodendroglioma 5Waldenstrom Macroglobulinemia 4Recurrence 4Lymphoma, T-Cell 4Lymphoma, B-Cell 4Leukemia, Myeloid, Chronic-Phase 4Leukemia, Myeloid, Acute 4Myelodysplastic Syndromes 3Lymphoma, T-Cell, Peripheral 3Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 3

Interventions

Melphalan 3thymoglobulin 1sargramostim 1romidepsin 1keyhole-limpet hemocyanin 1ixazomib 1Thalidomide 1Tablets 1Streptozocin 1Radiosurgery 1Radiation 1Mercaptopurine 1Leucovorin 1Ketoconazole 1Fulvestrant 1Floxuridine 1FANG vaccine 1Docetaxel 1Clinical Trials, Phase II as Topic 1Carmustine 1Antilymphocyte Serum 1Alpelisib 1Alendronate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Genetic Diseases, Inborn × Carmustine × Clear all
NCT00004688 2015-03-25

Phase II Study of Carmustine, Streptozocin, and Mercaptopurine for Refractory or Recurrent Brain Neoplasms

FDA Office of Orphan Products Development

Phase 2 Completed
35 enrolled
CNS

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Oligodendroglioma, Genetic Diseases, Inborn, Rare Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡